Weiss Multi Strategy Advisers LLC Mirati Therapeutics, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $623,701 - $1.41 Million	-15,927 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $311,544 - $620,335	-4,109 Reduced 20.51%	15,927 $1.31 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.32 Million - $1.91 Million	10,036 Added 100.36%	20,036 $2.94 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $147,192 - $197,679	-1,114 Reduced 10.02%	10,000 $1.77 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $1.6 Million - $2 Million	11,114 New	11,114 $1.8 Million

Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $147,636 - $205,875	-929 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $336,415 - $498,800	-2,076 Reduced 69.08%	929 $204,000
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $1.05 Million - $1.55 Million	-9,288 Reduced 75.56%	3,005 $499,000
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $813,064 - $1.36 Million	-11,291 Reduced 47.88%	12,293 $1.4 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $738,551 - $1.23 Million	10,584 Added 81.42%	23,584 $1.81 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $919,880 - $1.68 Million	13,000 New	13,000 $1.68 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.